Ocean Biomedical
Ocean Biomedical is dedicated to accelerating medical discoveries through innovative partnerships with top-tier researchers and institutions. They focus on translating promising scientific research into transformative medicines, addressing complex health problems such as lung cancer, pulmonary fibrosis, and malaria. Their mission is to bridge the gap between basic research and clinical development, ensuring that safe and effective medicines reach patients worldwide efficiently.
Industries
Nr. of Employees
small (1-50)
Ocean Biomedical
Providence, Rhode Island, United States, North America
Patents
Products
Therapeutic antibody program for non-small cell lung cancer
Development of monoclonal antibody therapeutics designed to modulate tumor and immune checkpoint pathways for treatment of non-small cell lung cancer and other oncology indications.
Enzyme-targeted therapy for pulmonary fibrosis
Preclinical development of therapies that manipulate specific enzymes to reduce fibrosis in lung tissue with reduced systemic toxicity, aimed at idiopathic pulmonary fibrosis and related disorders.
Malaria vaccine program based on antibody discoveries
Vaccine candidate development derived from identification of distinct human antibodies associated with protection, with progression planning toward Phase 1 clinical trials and parallel therapeutic approaches.
Chitinase-targeting therapeutics and bispecific approaches
Programs focused on modulation of chitinase-related pathways and multispecific constructs for indications including fibrosis and oncology, advanced toward early clinical testing timelines.
Therapeutic antibody program for non-small cell lung cancer
Development of monoclonal antibody therapeutics designed to modulate tumor and immune checkpoint pathways for treatment of non-small cell lung cancer and other oncology indications.
Enzyme-targeted therapy for pulmonary fibrosis
Preclinical development of therapies that manipulate specific enzymes to reduce fibrosis in lung tissue with reduced systemic toxicity, aimed at idiopathic pulmonary fibrosis and related disorders.
Malaria vaccine program based on antibody discoveries
Vaccine candidate development derived from identification of distinct human antibodies associated with protection, with progression planning toward Phase 1 clinical trials and parallel therapeutic approaches.
Chitinase-targeting therapeutics and bispecific approaches
Programs focused on modulation of chitinase-related pathways and multispecific constructs for indications including fibrosis and oncology, advanced toward early clinical testing timelines.
Services
Structuring licensing deals and forming partner subsidiaries to align incentives between inventors and host institutions and provide funding for development.
End-to-end program management to advance preclinical assets into clinical-ready candidates, including funding allocation, regulatory planning, and coordination of manufacturing pathways.
Long-term collaborations with research institutions to provide ongoing support and early access to promising discoveries.
Support for market access, payer strategy, KOL engagement, and launch planning to prepare assets for commercialization.
Structuring licensing deals and forming partner subsidiaries to align incentives between inventors and host institutions and provide funding for development.
End-to-end program management to advance preclinical assets into clinical-ready candidates, including funding allocation, regulatory planning, and coordination of manufacturing pathways.
Long-term collaborations with research institutions to provide ongoing support and early access to promising discoveries.
Support for market access, payer strategy, KOL engagement, and launch planning to prepare assets for commercialization.
Expertise Areas
- Translational research and bench-to-clinic development
- Antibody discovery and therapeutic antibody development
- Vaccine development
- Preclinical safety and toxicology
Key Technologies
- Monoclonal antibody discovery
- Bispecific antibody constructs
- Vaccine antigen selection
- Preclinical in vivo and in vitro models